Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Goldfinch Bio Inc.

www.goldfinchbio.com

Latest From Goldfinch Bio Inc.

Start-Up Quarterly Statistics: Financings Fell 17% To $2.84bn In Q2

A review of second quarter biopharma start-up deal-making and financing activity from Strategic Transactions showed a quarter-over-quarter drop in dollars raised despite multiple mega-rounds, including $100m-plus VC deals for SpringWorks and Fusion.

Deals Financing

Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.

Deals Business Strategies

Perfect Pitch: Rheos Raises $60m To Tune Immune Cells In Autoimmune Diseases

The Third Rock Ventures-funded start-up Rheos Medicines raised a $60m Series A round to study immune cell metabolism for drug targets that allow the company to fine-tune the immune system in autoimmune and inflammatory diseases, as well as cancer.

Financing Immune Disorders

Execs On The Move, March 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Goldfinch Bio Inc.
  • Senior Management
  • Anthony Johnson, MD, CEO
    Michael Broxson, CBO & COO
    Peter Mundel, MD, CSO
    Frank S Czerwiec, MD, PhD, CMO
  • Contact Info
  • Goldfinch Bio Inc.
    Phone: (617) 337-4200
    215 First St.
    4th Fl.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register